The nanoCelex platform is the proprietary process developed by AbCelex Technologies that enables target discovery, as well as identification, isolation, and engineering of lead sdAb-based products. Once particular pathogen-binding sdAbs are identified via an initial screening process, AbCelex conducts additional screening and functional assays to select and ultimately develop the most promising sdAb candidates. Specifically, lead candidates comprise sdAbs with the ability to markedly reduce growth and/or pathogenicity of multiple strains of a particular pathogen. Once identified, promising sdAb candidates are further optimized at the nucleic acid sequence level to enhance both stability and efficacy. The nanoCelex platform enables AbCelex to quickly move through initial discovery and development to efficient commercialization of novel sdAbs suitable for multiple animal health applications.